Tags

Type your tag names separated by a space and hit enter

Covid-19 vaccines and variants of concern: A review.
Rev Med Virol. 2022 07; 32(4):e2313.RM

Abstract

Since the outbreak of coronavirus disease 2019 (Covid-19) in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the number of confirmed infections has risen to more than 242 million worldwide, with nearly 5 million deaths. Currently, nine Covid-19 vaccine candidates based on the original Wuhan-Hu-1 strain are at the forefront of vaccine research. All nine had an efficacy over 50% against symptomatic Covid-19 disease: NVX-CoV2373 (∼96%), BNT162b2 (∼95%), mRNA-1273 (∼94%), Sputnik V (∼92%), AZD1222 (∼81%), BBIBP-CorV (∼79%), Covaxin (∼78%), Ad26.CoV.S (∼66%) and CoronaVac (∼51%). However, vaccine efficacy (VE) can be jeopardised by the rapid emergence and spread of SARS-CoV-2 variants of concern (VOCs) that could escape from neutralising antibodies and/or cell-mediated immunity. Rare adverse events have also been reported soon after administration of viral vector and mRNA vaccines. Although many Covid-19 vaccines have been developed, additional effective vaccines are still needed to meet the global demand. Promising Covid-19 vaccines such as WIBP-CorV, AD5-nCOV, ZyCoV-D, CVnCoV, EpiVacCorona and ZF2001 have advanced to clinical studies. This review describes the most relevant mutations in the SARS-CoV-2 spike protein, discusses VE against VOCs, presents rare adverse events after Covid-19 vaccination and introduces some promising Covid-19 vaccine candidates.

Links

PMC Free PDF

Authors+Show Affiliations

Hadj Hassine I
Unité de Recherche UR17ES30 'Génomique, Biotechnologie et Stratégies Antivirales', Institut Supérieur de Biotechnologie, Université de Monastir, Monastir, Tunisia.

MeSH

Antibodies, ViralBNT162 VaccineCOVID-19COVID-19 VaccinesChAdOx1 nCoV-19HumansSARS-CoV-2Spike Glycoprotein, CoronavirusVaccines, Synthetic

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

34755408

Citation

Hadj Hassine, Ikbel. "Covid-19 Vaccines and Variants of Concern: a Review." Reviews in Medical Virology, vol. 32, no. 4, 2022, pp. e2313.
Hadj Hassine I. Covid-19 vaccines and variants of concern: A review. Rev Med Virol. 2022;32(4):e2313.
Hadj Hassine, I. (2022). Covid-19 vaccines and variants of concern: A review. Reviews in Medical Virology, 32(4), e2313. https://doi.org/10.1002/rmv.2313
Hadj Hassine I. Covid-19 Vaccines and Variants of Concern: a Review. Rev Med Virol. 2022;32(4):e2313. PubMed PMID: 34755408.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Covid-19 vaccines and variants of concern: A review. A1 - Hadj Hassine,Ikbel, Y1 - 2021/11/09/ PY - 2021/10/25/revised PY - 2021/10/06/received PY - 2021/10/25/accepted PY - 2021/11/11/pubmed PY - 2022/7/9/medline PY - 2021/11/10/entrez KW - Covid-19 vaccines KW - SARS-CoV-2 KW - rare adverse events KW - vaccine efficacy KW - variants of concern SP - e2313 EP - e2313 JF - Reviews in medical virology JO - Rev Med Virol VL - 32 IS - 4 N2 - Since the outbreak of coronavirus disease 2019 (Covid-19) in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the number of confirmed infections has risen to more than 242 million worldwide, with nearly 5 million deaths. Currently, nine Covid-19 vaccine candidates based on the original Wuhan-Hu-1 strain are at the forefront of vaccine research. All nine had an efficacy over 50% against symptomatic Covid-19 disease: NVX-CoV2373 (∼96%), BNT162b2 (∼95%), mRNA-1273 (∼94%), Sputnik V (∼92%), AZD1222 (∼81%), BBIBP-CorV (∼79%), Covaxin (∼78%), Ad26.CoV.S (∼66%) and CoronaVac (∼51%). However, vaccine efficacy (VE) can be jeopardised by the rapid emergence and spread of SARS-CoV-2 variants of concern (VOCs) that could escape from neutralising antibodies and/or cell-mediated immunity. Rare adverse events have also been reported soon after administration of viral vector and mRNA vaccines. Although many Covid-19 vaccines have been developed, additional effective vaccines are still needed to meet the global demand. Promising Covid-19 vaccines such as WIBP-CorV, AD5-nCOV, ZyCoV-D, CVnCoV, EpiVacCorona and ZF2001 have advanced to clinical studies. This review describes the most relevant mutations in the SARS-CoV-2 spike protein, discusses VE against VOCs, presents rare adverse events after Covid-19 vaccination and introduces some promising Covid-19 vaccine candidates. SN - 1099-1654 UR - https://www.unboundmedicine.com/medline/citation/34755408/Covid_19_vaccines_and_variants_of_concern:_A_review_ DB - PRIME DP - Unbound Medicine ER -